Chloramphenicol sodium succinate

This classification denotes a protein synthesis inhibitor and antibiotic with the molecular structure C15H15CL2N2O8.NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 872109HX6B chemically known as butanedioic acid, mono(2-((2,2-dichloroacetyl)amino)-3-hydroxy-3-(4-nitrophenyl)propyl) ester, monosodium salt, (r-(r*,r*))-, but more commonly known as chloramphenicol sodium succinate, which bears US NIH Compound Identifier 298. European Medicines Agency schedules Chloramphenicol sodium succinate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01207MIG. Most nations, for tariff and trade purposes, schedule chloramphenicol sodium succinate under HS 29414000. As of Q4 2014, CHLORAMPHENICOL SODIUM SUCCINATE remains US FDA's Preferred Term for this commodity. Chloramphenicol sodium succinate bears US NLM identifiers UMLS ID C0109354 and NCI Concept Code C47972. SMILES: C1CC(CCC1[C@H]([C@@H](COC(=O)CCC(=O)[O-])NC(=O)C(CL)CL)O)[N+](=O)[O-].[NA+].